Teslas Trading Volume Soars Amid 5.62% Gain, Leading Market Momentum
Monday, Nov 18, 2024 5:31 pm ET
2min read 1. Tesla (Nasdaq: TSLA)
Tesla gained solidly by 5.62%, with the trading volume of 42.75B. Tesla reaffirmed its outperformance rating by Wedbush, with a target price of $400. The company reported Q3 revenue of $71.983 billion, with a net income of $4.821 billion. Tesla dismissed the rumors of FSD licensing discussions with SAIC.
2. Nvidia (Nasdaq: NVDA)
Nvidia dipped mildly by -1.29%, with the trading volume of 30.78B. NVIDIA is maintaining a "buy" rating with a target price of $200 by Rosenblatt. The company's Blackwell processors face overheating issues, impacting delivery schedules. Bank of America notes NVIDIA's upcoming earnings could significantly influence market dynamics.
3. Microstrategy Incorporated (Nasdaq: MSTR)
Microstrategy Incorporated surged by 12.96%, with the trading volume of 11.98B. MicroStrategy purchased approximately 51,780 bitcoins for around $4.6 billion in cash.
4. Apple (Nasdaq: AAPL)
Apple gained mildly by 1.34%, with the trading volume of 10.16B. Apple faces significant iPhone price hikes due to new tariffs, considers launching a self-branded TV, and lists iPhone XS Max and iPhone 6s Plus as obsolete. Foxconn, an Apple supplier, modified its recruitment ads in India to remove age, gender, and marital status criteria.
5. Microsoft (Nasdaq: MSFT)
Microsoft gained mildly by 0.18%, with the trading volume of 9.97B. Microsoft has opened its first Japanese R&D center in Tokyo, focusing on integrating robotics with AI. Additionally, Microsoft secured a patent for a tri-fold phone, hinting at future developments in foldable devices, potentially paving the way for the Surface Phone.
6. Palantir Technologies (NYSE: PLTR)
Palantir Technologies plunged by -6.87%, with the trading volume of 8.37B. Palantir witnessed a surge in AI application investments, with a notable increase in trading volume and significant annual growth, highlighting its position as a major player in the AI sector.
7. Coinbase Global (Nasdaq: COIN)
Coinbase Global surged by 6.39%, with the trading volume of 8.01B. Needham maintains a Buy rating on Coinbase Global with a target price of $375. Coinbase Global reported revenue of $42.92 billion for Q3 2024, ending September 30.
8. Meta Platforms (Nasdaq: META)
Meta Platforms gained mildly by 0.06%, with the trading volume of 7.91B. Meta's total trading volume last week reached $380.27 billion with shares closing at $554.08, reflecting significant activity in the market but facing a weekly decline against broader indices.
9. Amazon (Nasdaq: AMZN)
Amazon.Com dipped mildly by -0.45%, with the trading volume of 7.29B. Amazon leverages Pinduoduo's strategies in cross-border e-commerce competition while optimizing supply chain systems using Amazon Web Services.
10. Eli Lilly Andmpany (NYSE: LLY)
Eli Lilly Andmpany dipped mildly by -2.50%, with the trading volume of 6.60B. Eli Lilly's Tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro, significantly reduces heart failure risk for HFpEF patients with obesity. Eli Lilly also sued the U.S. HRSA over conflicts regarding 340B drug discounts.
Tesla gained solidly by 5.62%, with the trading volume of 42.75B. Tesla reaffirmed its outperformance rating by Wedbush, with a target price of $400. The company reported Q3 revenue of $71.983 billion, with a net income of $4.821 billion. Tesla dismissed the rumors of FSD licensing discussions with SAIC.
2. Nvidia (Nasdaq: NVDA)
Nvidia dipped mildly by -1.29%, with the trading volume of 30.78B. NVIDIA is maintaining a "buy" rating with a target price of $200 by Rosenblatt. The company's Blackwell processors face overheating issues, impacting delivery schedules. Bank of America notes NVIDIA's upcoming earnings could significantly influence market dynamics.
3. Microstrategy Incorporated (Nasdaq: MSTR)
Microstrategy Incorporated surged by 12.96%, with the trading volume of 11.98B. MicroStrategy purchased approximately 51,780 bitcoins for around $4.6 billion in cash.
4. Apple (Nasdaq: AAPL)
Apple gained mildly by 1.34%, with the trading volume of 10.16B. Apple faces significant iPhone price hikes due to new tariffs, considers launching a self-branded TV, and lists iPhone XS Max and iPhone 6s Plus as obsolete. Foxconn, an Apple supplier, modified its recruitment ads in India to remove age, gender, and marital status criteria.
5. Microsoft (Nasdaq: MSFT)
Microsoft gained mildly by 0.18%, with the trading volume of 9.97B. Microsoft has opened its first Japanese R&D center in Tokyo, focusing on integrating robotics with AI. Additionally, Microsoft secured a patent for a tri-fold phone, hinting at future developments in foldable devices, potentially paving the way for the Surface Phone.
6. Palantir Technologies (NYSE: PLTR)
Palantir Technologies plunged by -6.87%, with the trading volume of 8.37B. Palantir witnessed a surge in AI application investments, with a notable increase in trading volume and significant annual growth, highlighting its position as a major player in the AI sector.
7. Coinbase Global (Nasdaq: COIN)
Coinbase Global surged by 6.39%, with the trading volume of 8.01B. Needham maintains a Buy rating on Coinbase Global with a target price of $375. Coinbase Global reported revenue of $42.92 billion for Q3 2024, ending September 30.
8. Meta Platforms (Nasdaq: META)
Meta Platforms gained mildly by 0.06%, with the trading volume of 7.91B. Meta's total trading volume last week reached $380.27 billion with shares closing at $554.08, reflecting significant activity in the market but facing a weekly decline against broader indices.
9. Amazon (Nasdaq: AMZN)
Amazon.Com dipped mildly by -0.45%, with the trading volume of 7.29B. Amazon leverages Pinduoduo's strategies in cross-border e-commerce competition while optimizing supply chain systems using Amazon Web Services.
10. Eli Lilly Andmpany (NYSE: LLY)
Eli Lilly Andmpany dipped mildly by -2.50%, with the trading volume of 6.60B. Eli Lilly's Tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro, significantly reduces heart failure risk for HFpEF patients with obesity. Eli Lilly also sued the U.S. HRSA over conflicts regarding 340B drug discounts.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.